An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)
Clinical trial NCT01806298 · COMPLETED
Trial details
- NCT number
- NCT01806298
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2013-06-01
- Primary completion
- 2016-03-01
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.